DDInter802 DDInter1676
Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sources, such as _Galanthus nivalis_. Galantamine was first studied in paralytic and neuropathic conditions, such as myopathies and postpolio paralytic conditions, and for reversal of neuromuscular blockade.[A182993,A201968] Following the discovery of its AChE-inhibiting properties, the cognitive effects of galantamine were studied in a wide variety of psychiatric disorders such as mild cognitive impairment, cognitive impairment in schizophrenia and bipolar disorder, and autism; however, re-development of the drug for Alzheimer’s disease did not commence until the early 1990s due to difficulties in extraction and
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Galantamine {u} (Compound) resembles {v} (Compound) Dihydrocodeine
Galantamine {u} (Compound) resembles {v} (Compound) Codeine
Galantamine {u} (Compound) treats {v} (Disease) Alzheimer's disease
Galantamine {u} (Compound) binds {v} (Gene) CHRND
Galantamine {u} (Compound) upregulates {v} (Gene) HERC6
Galantamine {u} (Compound) downregulates {v} (Gene) MBOAT7
Galantamine {u} (Compound) causes {v} (Side Effect) Hypotension
Galantamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hyoscyamine
Galantamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cyclizine
Galantamine {u} may lead to a major life threatening interaction when taken with {v} Bupropion
Galantamine (Compound) resembles Dihydrocodeine (Compound)
Galantamine (Compound) resembles Codeine (Compound)
Galantamine (Compound) treats Alzheimer's disease (Disease)
Galantamine (Compound) binds CHRND (Gene)
Galantamine (Compound) upregulates HERC6 (Gene)
Galantamine (Compound) downregulates MBOAT7 (Gene)
Galantamine (Compound) causes Hypotension (Side Effect)
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine
Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine
Galantamine may lead to a major life threatening interaction when taken with Bupropion